Loading
Tasca Therapeutics makes pills that block cancer-driving proteins by plugging a pocket where the protein normally holds a fatty molecule. Its first medicine, CP-383, began its first human trial in advanced solid tumours in September 2025.
Tasca Therapeutics is a clinical-stage company whose discovery platform identifies and maps lipid-binding pockets on proteins, including sites on auto-palmitoylated proteins, and designs small molecules against them. Its first-in-class lead, CP-383, is designed to modulate an oncogenic signalling pathway that the company has not named publicly; the launch release said it would first be evaluated in small cell lung, colorectal, head and neck and brain cancers. Tasca launched on 10 December 2024 with a USD 52 million Series A co-led by Regeneron Ventures and Cure Ventures with participation from the Invus Group, and on 16 September 2025 announced the first patient dosed in a phase 1/2 dose escalation and expansion trial of CP-383 in advanced solid tumours. Scientific founders are Xu Wu, David Fisher and Duojia Pan; co-founder Milenko Cicmil is chief executive.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Co-led by Regeneron Ventures and Cure Ventures, with the Invus Group | 2024 | $52M | tascatx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/